Systemic Lupus Erythematosus and Accelerated Aging — LUPAGE  

Systemic Lupus Erythematosus Clinical Trial

Official title: Systemic Lupus Erythematosus and Accelerated Aging

Status Recruiting

Clinical Trial Summary

The study aims at evaluating the phenomena of immune system aging in patients with Systemic lupus erythematosus.

Clinical Trial Description

Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease characterized by a breakdown of tolerance against nuclear antigens. Thanks to improvements during the last decades in diagnosis, therapeutics and medical care, the lifespan of SLE patients has remarkably increased. However, standardized mortality ratio are still high in this population, with an increased mortality and morbidity associated with cardiovascular events and infectious events. Interestingly, these conditions are more commonly found during old age in the general population, raising the question of the presence of an acceleration of the aging process in SLE patients. It has been demonstrated that the aging of the immune system, i.e. immunosenescence, is a key player in the development of many age-related diseases. The acceleration of immunosenescence, as it is observed during chronic viral infections for example, could favor the premature occurrence of clinical manifestations of accelerated aging. The exact contribution of such phenomenon in the context of SLE has, so far, never been explored. Here, the investigators propose to perform a comprehensive study of the phenomena of immune system aging in patients with SLE in comparison to age-matched healthy controls. The study will recruit 50 SLE patients followed in Bordeaux University Hospital. Among classical disease activity information, blood samples will be collected at study visit to extensively evaluate immune system aging. Fundamental research will be realized on patients' samples. Patients will be included within their usual follow-up. No extra visit will be needed, and blood samples will be drawn at the same time as those drawn for clinical purposes. ;

Related Conditions & MeSH terms

• Lupus Erythematosus, Systemic
• Systemic Lupus Erythematosus

• NCT number: NCT05698173
• Study type: Interventional
• Source: University Hospital, Bordeaux
• Contact: Noemie GENSOUS, MD
• Phone: (0)5 56 79 58 28
• Email: noemie.gensous@chu-bordeaux.fr
• Status: Recruiting
• Phase: N/A
• Start date: September 8, 2023
• Completion date: September 2025